SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
Adding bevacizumab to the oral chemotherapy trifluridine-tipiracil lengthened survival by about three months in patients with colorectal cancer that had already been treated with two regimens, making the combination the standard third-line treatment.
Overview
Phase 3 trial of 492 patients with metastatic colorectal cancer after two prior regimens randomised to trifluridine-tipiracil with or without bevacizumab.
Median overall survival was 10.8 versus 7.5 months (hazard ratio 0.61) and median progression-free survival 5.6 versus 2.4 months, with a longer time to worsening performance status and no unexpected toxicity.
- Median overall survival 10.8 vs 7.5 months; hazard ratio 0.61.
- Median progression-free survival 5.6 vs 2.4 months.
Trifluridine-tipiracil plus bevacizumab is now the preferred third-line option for most patients regardless of KRAS status, including KRAS G12C tumours once targeted therapy is exhausted.
- Open-label; benefit was seen regardless of prior bevacizumab exposure but subgroup sizes were limited.
Similar pages
not linked directly; found by shared links- Key paperGOG 240: bevacizumab added to chemotherapy for advanced cervical cancer
- Key paperKRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer
Shares KRAS G12C-mutant colorectal cancer, New England Journal of Medicine.
- Key paperHearing improvement after bevacizumab in patients with neurofibromatosis type 2
- Key paperCodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer
Shares KRAS G12C-mutant colorectal cancer, New England Journal of Medicine.
- TreatmentTrifluridine/tipiracil
- PathwayColorectal cancer (KEGG map)